原発性胆汁性胆管炎(PBC)治療法の世界市場2019-2023

◆英語タイトル:Global Primary Biliary Cholangitis Therapeutics Market 2019-2023
◆商品コード:IRTNTR31508
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月17日
◆ページ数:131
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、原発性胆汁性胆管炎(PBC)治療法の世界市場について調べ、原発性胆汁性胆管炎(PBC)治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、原発性胆汁性胆管炎(PBC)治療法の市場規模をセグメンテーション別(製品別(オカリバ、ウルソジオール、その他)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は原発性胆汁性胆管炎(PBC)治療法の世界市場規模が2019-2023期間中に年平均10%成長すると予測しています。
・サマリー
・レポートの範囲
・原発性胆汁性胆管炎(PBC)治療法の市場状況
・原発性胆汁性胆管炎(PBC)治療法の市場規模
・原発性胆汁性胆管炎(PBC)治療法の市場予測
・原発性胆汁性胆管炎(PBC)治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(オカリバ、ウルソジオール、その他)
・原発性胆汁性胆管炎(PBC)治療法の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Primary Biliary Cholangitis Therapeutics Market: About this market

Primary biliary cholangitis is a chronic autoimmune disease in which intrahepatic bile ducts are damaged over a period of time. Technavio’s primary biliary cholangitis therapeutics market analysis considers sales of OCALIVA, ursodiol, and others. Our analysis also considers the sales of primary biliary cholangitis therapeutics in Asia, Europe, North America, ROW. In 2018, the OCALIVA segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as strong efficacy of OCALIVA to target the T-cells that are known to cause primary biliary cholangitis will play a significant role in the OCALIVA segment to maintain its market position. Also, our global primary biliary cholangitis therapeutics market report looks at factors such as increasing collaborations, growing risk factors, and rising awareness campaigns to reduce further complications. However, asymptomatic nature of the disease, lack of approved therapies, and availability of alternative therapies may hamper the growth of the primary biliary cholangitis therapeutics industry over the forecast period.

Global Primary Biliary Cholangitis Therapeutics Market: Overview

Growing awareness campaigns to reduce further complications

To increase the awareness of the indication, various organizations and the vendors in the global primary biliary cholangitis therapeutics market are conducting awareness campaigns. For instance, the PBCers Organization is a non-profit organization that focuses on increasing the awareness of the indication globally. The organization also focuses on funding the research on the development of novel therapies to treat primary biliary cholangitis. This will boost the sales of primary biliary cholangitis therapeutics and lead to the expansion of the global primary biliary cholangitis therapeutics market at a CAGR of close to 10% during the forecast period.

Advent of regenerative therapy

Research on regenerative therapy is gaining traction as the liver transplant method of treatment causes post-surgery complications to patients. Also, at present, there is no cure for the indication other than liver transplant due to the recurring nature of the disease. This is encouraging researchers to conduct study on stem cell transplantation, which can replace destroyed cells in the bile duct. This ongoing research is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global primary biliary cholangitis therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of few major players, the global primary biliary cholangitis therapeutics market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics manufacturers, that include Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

OCALIVA – Market size and forecast 2018-2023

Ursodiol – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

Strong pipeline

Increasing drug designations

Advent of regenerative therapy

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Abbott Laboratories

Allergan Plc

Eli Lilly and Co.

Intercept Pharmaceuticals Inc.

Takeda Pharmaceutical Co. Ltd.

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Global primary biliary cholangitis therapeutics market pipeline: Overview

Exhibit 18: Global primary biliary cholangitis therapeutics market pipeline: Snapshot

Exhibit 19: Product – Market share 2018-2023 (%)

Exhibit 20: Comparison by product

Exhibit 21: OCALIVA – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: OCALIVA – Year-over-year growth 2019-2023 (%)

Exhibit 23: Ursodiol – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Ursodiol – Year-over-year growth 2019-2023 (%)

Exhibit 25: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Others – Year-over-year growth 2019-2023 (%)

Exhibit 27: Market opportunity by product

Exhibit 28: Customer landscape

Exhibit 29: Market share by geography 2018-2023 (%)

Exhibit 30: Geographic comparison

Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: North America – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in North America

Exhibit 34: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Europe

Exhibit 37: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in Asia

Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 42: Top 3 countries in ROW

Exhibit 43: Key leading countries

Exhibit 44: Market opportunity

Exhibit 45: Impact of drivers and challenges

Exhibit 46: Vendor landscape

Exhibit 47: Landscape disruption

Exhibit 48: Vendors covered

Exhibit 49: Vendor classification

Exhibit 50: Market positioning of vendors

Exhibit 51: Abbott Laboratories – Vendor overview

Exhibit 52: Abbott Laboratories – Business segments

Exhibit 53: Abbott Laboratories – Organizational developments

Exhibit 54: Abbott Laboratories – Geographic focus

Exhibit 55: Abbott Laboratories – Segment focus

Exhibit 56: Abbott Laboratories – Key offerings

Exhibit 57: Abbott Laboratories – Key customers

Exhibit 58: Allergan Plc – Vendor overview

Exhibit 59: Allergan Plc – Business segments

Exhibit 60: Allergan Plc – Organizational developments

Exhibit 61: Allergan Plc – Geographic focus

Exhibit 62: Allergan Plc – Segment focus

Exhibit 63: Allergan Plc – Key offerings

Exhibit 64: Allergan Plc – Key customers

Exhibit 65: Eli Lilly and Co. – Vendor overview

Exhibit 66: Eli Lilly and Co. – Business segments

Exhibit 67: Eli Lilly and Co. – Organizational developments

Exhibit 68: Eli Lilly and Co. – Geographic focus

Exhibit 69: Eli Lilly and Co. – Segment focus

Exhibit 70: Eli Lilly and Co. – Key offerings

Exhibit 71: Eli Lilly and Co. – Key customers

Exhibit 72: Intercept Pharmaceuticals Inc. – Vendor overview

Exhibit 73: Intercept Pharmaceuticals Inc. – Business segments

Exhibit 74: Intercept Pharmaceuticals Inc. – Organizational developments

Exhibit 75: Intercept Pharmaceuticals Inc. – Geographic focus

Exhibit 76: Intercept Pharmaceuticals Inc. – Key offerings

Exhibit 77: Intercept Pharmaceuticals Inc. – Key customers

Exhibit 78: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 79: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 81: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 82: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 83: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Definition of market positioning of vendors



【掲載企業】

Abbott Laboratories
Allergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[原発性胆汁性胆管炎(PBC)治療法の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆